Hepion pharmaceuticals to present at the 7th obesity & nash drug development summit

Edison, n.j., nov. 28, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that it will present at the 7th obesity & nash drug development summit taking place november 27 – 29, 2023 in boston.
HEPA Ratings Summary
HEPA Quant Ranking